Perspective Therapeutics To Discuss Data On [212Pb]VMT-α-NET Presented At The 2024 NANETS Multidisciplinary NET Medical Symposium On November 21, 2024
Perspective Therapeutics To Discuss Data On [212Pb]VMT-α-NET Presented At The 2024 NANETS Multidisciplinary NET Medical Symposium On November 21, 2024
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago.
纽交所上市公司Perspective Therapeutics, Inc.（"Perspective"或"公司"）（NYSE:CATX）是一家放射性药物公司，正在开创癌症全身治疗的爱文思控股应用新领域，今天发布了关于即将在2024年11月21日至23日在芝加哥举行的2024年北美神经内分泌肿瘤学会（NANETS）多学科NEt医疗研讨会上展示公司赞助的[212Pb]VMt-α-NEt第1/2a期临床试验初步结果的详细信息。
The presentation entitled "Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)" will be presented by Richard L. Wahl, MD, (Professor of Radiology, Mallinckrodt Institute of Radiology at Washington University School of Medicine) on Friday, November 22, 2024 at 9:05 am CT. Results of the study are also available as a poster (number C-37) at the NANETS symposium.
Richard L. Wahl, MD（华盛顿大学医学院Mallinckrodt放射学研究所教授）将于2024年11月22日星期五上午9:05在NANETS研讨会上作题为"SSTR2表达神经内分泌肿瘤（NETs）[212Pb]VMt-α-NEt的初步安全性和有效性数据"的报告。研究结果也可作为海报（编号C-37）在NANETS研讨会上查看。
